Table 2. Virological response at end of treatment and at week 4, 12 and 24 of follow-up (all treated patients) and relapse at week 4, 12 and 24 of follow-up.
BOC, boceprevir; CI, 95% confidence interval; MCB, mericitabine; P/R, peginterferon alfa-2a/ribavirin; TVR, telaprevir
| DYNAMO 1 | DYNAMO 2 | ||||||
|---|---|---|---|---|---|---|---|
| Arm A | Arm B | Arm C | Arm A | Arm B | Arm C | Arm D | |
| MCB + BOC + P/R × 24 weeks | MCB + BOC + P/R × 24 weeks, then BOC + P/R × 24 weeks | P/R lead-in × 4 weeks, then BOC + P/R × 44 weeks* | MCB + TVR + P/R × 12 weeks, then MCB + P/R × 12 weeks | MCB + TVR + P/R × 12 weeks, then MCB + P/R ×12 weeks, then P/R × 24 weeks | MCB + TVR + P/R × 12 weeks, then P/R × 36 weeks | TVR + P/R × 12 weeks, then P/R × 36 weeks* | |
| n = 25 | n = 20 | n = 12 | n = 21 | n = 23 | n = 24 | n = 11 | |
| Response at actual end of treatment, n (%; CI) | 23 (92.0; 75.0, 97.8) | 17 (85.0; 64.0, 94.8) | 8 (66.7; 39.1, 86.2) | 21 (100; 84.5, 100) | 22 (95.7; 79.0, 99.2) | 17 (70.8; 50.8, 85.1) | 10 (90.9; 62.3, 98.4) |
| SVR4, n (%; CI) | 15 (60.0; 40.7, 76.6) | 15 (75.0; 53.1, 88.8) | 4 (33.3; 13.8, 60.9) | 18 (85.7; 65.4, 95.0) | 22 (95.7; 79.0, 99.2) | 17 (70.8; 50.8, 85.1) | 10 (90.9; 62.3, 98.4) |
| SVR12, n (%; CI) | 15 (60.0; 40.7, 76.6) | 14 (70.0; 48.1, 85.5) | 4 (33.3; 13.8, 60.9) | 17 (81.0; 60.0, 92.3) | 22 (95.7; 79.0, 99.2) | 17 (70.8; 50.8, 85.1) | 10 (90.9; 62.3, 98.4) |
| SVR24, n (%; CI) | 15 (60.0; 40.7, 76.6) | 14 (70.0; 48.1, 85.5) | 4 (33.3; 13.8, 60.9) | 16 (76.2; 54.9, 89.4) | 22 (95.7; 79.0, 99.2) | 17 (70.8; 50.8, 85.1) | 10 (90.9; 62.3, 98.4) |
| Relapse at follow-up Week 4, n/n (%; CI) | 8/22 (36.4; 19.7, 57.0) | 1/16 (6.3; 1.1, 28.3) | 3/7 (42.9; 15.8, 75.0) | 1/19 (5.3; 0.9, 24.6) | 0/22 (0; 0, 14.9) | 0/15 (0; 0, 20.4) | 0/10 (0; 0, 27.8) |
| Relapse at follow-up Week 12, n/n (%; CI) | 8/23 (34.8; 18.8, 55.1) | 2/16 (12.5; 3.5, 36.0) | 3/7 (42.9; 15.8, 75.0) | 2/19 (10.5; 2.9, 31.4) | 0/22 (0; 0, 14.9) | 0/17 (0; 0, 18.4) | 0/10 (0; 0, 27.8) |
| Relapse at follow-up Week 24, n/n (%; CI) | 8/23 (34.8; 18.8, 55.1) | 2/16 (12.5; 3.5, 36.0) | 3/7 (42.9; 15.8, 75.0) | 3/19 (15.8; 5.5, 37.6) | 0/22 (0; 0, 14.9) | 0/17 (0; 0, 18.4) | 0/10 (0; 0, 27.8) |
* MCB could be added to treatment at the investigator’s discretion